Evidence map›Paper›PMID 34837341›Full record

ArticleCancer medicine2022

Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma.

Sneha R Rao, Alexander L Lazarides, Bruce L Leckey, Whitney O Lane, Julia D Visgauss, Jason A Somarelli, David G Kirsch, Nicole A Larrier, Brian E Brigman, Dan G Blazer and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. The Role of [Current oncology (Toronto, Ont.) · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sneha R RaoDepartment of Orthopaedics, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-3319-5049
Alexander L LazaridesDepartment of Orthopaedics, Duke University, Durham, North Carolina, USA.ORCID 0000-0003-0704-1529
Bruce L LeckeyDepartment of Pathology, Duke University, Durham, North Carolina, USA.
Whitney O LaneDepartment of Surgery, Duke University, Durham, North Carolina, USA.
Julia D VisgaussDepartment of Orthopaedics, Duke University, Durham, North Carolina, USA.
Jason A SomarelliDepartment of Medicine, Duke University, Durham, North Carolina, USA.
David G KirschDepartment of Radiation Oncology, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-2086-205X
Nicole A LarrierDepartment of Radiation Oncology, Duke University, Durham, North Carolina, USA.
Brian E BrigmanDepartment of Orthopaedics, Duke University, Durham, North Carolina, USA.
Dan G BlazerDepartment of Surgery, Duke University, Durham, North Carolina, USA.
Diana M CardonaDepartment of Pathology, Duke University, Durham, North Carolina, USA.
William C EwardDepartment of Orthopaedics, Duke University, Durham, North Carolina, USA.
Duke University · USDuke University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrent standard of care for most intermediate and high-grade soft-tissue sarcomas (STS) includes limb-preserving surgical resection with either neoadjuvant radiation therapy (NRT) or adjuvant radiation therapy. To date, there have been a few studies that attempt to correlate histopathologic response to NRT with oncologic outcomes in patients with STS.

methodsUsing our institutional database, we identified 58 patients who received NRT followed by surgical resection for primary intermediate or high-grade STS and 34 patients who received surgical resection without NRT but did receive adjuvant radiation therapy or did not receive any radiation therapy. We analyzed four histologic parameters of response to therapy: residual viable tumor, fibrosis/hyalinization, necrosis, and infarction (each ratiometrically determined). Data were stratified into two binary groups. Unadjusted, 5- and 10-year overall survival, and relapsed-free survival (RFS) were calculated using the Kaplan-Meier method.

resultsAnalysis of pathologic characteristics showed that patients treated with NRT demonstrate significantly higher tumor infarction, higher tumor fibrosis/hyalinization, and a lower percent viable tumor compared with patients not treated with NRT (p < 0.0001). Based on Kaplan-Meier curve analysis and multivariate cox proportional hazard model for OS and RFS, patients treated with NRT and showing >12.5% tumor fibrosis/hyalinization have significantly higher overall survival and recurrence-free survival at 5 and 10 years. DISCUSSION AND

conclusionWe have identified three histopathologic characteristics-fibrosis, hyalinization, and infarction-that may serve as predictive biomarkers of response to NRT for STS patients. Future prospective studies will be needed to confirm this association.

Indexed as

Neoadjuvant TherapyAgedDisease-Free SurvivalFemaleFibrosisHumansHyalinInfarctionKaplan-Meier EstimateMaleMiddle AgedNecrosisProportional Hazards ModelsRetrospective StudiesSarcomafibrosisneoadjuvant radiation therapysarcomasoft tissue

Identifiers

PMID34837341
PMCPMC8704179
OpenAlexW3217716937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.